Skip to main content
RYVU Therapeutics S.A. logo

RYVU Therapeutics S.A. — Investor Relations & Filings

Ticker · RVU ISIN · PLSELVT00013 LEI · 2594003WO9Q9HHAFL031 WAR Professional, scientific and technical activities
Open in API
Filings indexed 803 across all filing types
Latest filing 2025-12-10 Director's Dealing
Country PL Poland
Listing WAR RVU

About RYVU Therapeutics S.A.

https://ryvu.com/

Ryvu Therapeutics is a clinical-stage drug discovery and development company specializing in novel small molecule therapies for oncology. The company's research focuses on emerging biological targets and pathways, including kinase inhibition, synthetic lethality, and immuno-oncology, to develop precise cancer treatments. Its pipeline features several candidates in various stages of development. Key clinical-stage assets include Romaciclib (RVU120), a selective CDK8/19 kinase inhibitor for treating hematologic malignancies like acute myeloid leukemia (AML) and myelofibrosis, and Dapolsertib (MEN1703), a PIM/FLT3 inhibitor. The company also advances preclinical programs, such as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP deletion.

Recent filings

Filing Released Lang Actions
Zawiadomienia od osoby pełniącej obowiązki zarządcze w Spółce / Notifications from person discharging managerial responsibilities in the Company - Content (PL)
Director's Dealing Classification · 1% confidence The document is a notification regarding a change in share ownership by a company executive (CEO) and a related entity (Family Foundation). It specifically references Article 19 of the MAR (Market Abuse Regulation) regarding notifications of transactions by persons discharging managerial responsibilities. This type of disclosure, involving the transfer of shares by a director or closely associated person, is classified as a Director's Dealing.
2025-12-10 Polish
Prezentacja danych klinicznych dotyczących romacyklibu (RVU120) z badania REMARK oraz dapolsertibu (MEN1703) z badania JASPIS-01 na dorocznej konferencji Amerykańskiego Towarzystwa Hematologicznego...
AGM Information Classification · 1% confidence The document is an announcement from Ryvu Therapeutics regarding clinical trial data presented at the American Society of Hematology (ASH) meeting. It provides summaries of the REMARK and JASPIS-01 studies and explicitly states that the posters are available for download on the company's website. Since the document serves to announce the availability of these materials rather than being the primary scientific report itself, and it does not fit into specific financial categories like 10-K or ER, it is classified as a Regulatory Filing (RNS) as it functions as a corporate announcement.
2025-12-08 English
Prezentacja danych klinicznych dotyczących romacyklibu (RVU120) z badania REMARK oraz dapolsertibu (MEN1703) z badania JASPIS-01 na dorocznej konferencji Amerykańskiego Towarzystwa Hematologicznego...
AGM Information Classification · 1% confidence The document is a regulatory announcement from Ryvu Therapeutics S.A. regarding the presentation of clinical trial data (REMARK and JASPIS-01) at the American Society of Hematology (ASH) conference. It provides specific details on the study results, methodology, and safety data, and concludes by directing readers to the company's website to view the posters. Since it is a formal regulatory disclosure of company activity and clinical progress that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a general regulatory filing.
2025-12-08 Polish
Nowe dane kliniczne z badań romacyklibu (RVU120) RIVER-81 i POTAMI-61 prezentowane podczas dorocznej konferencji Amerykańskiego Towarzystwa Hematologicznego (ASH) 2025 / New Clinical Data from RIVE...
Regulatory Filings Classification · 1% confidence The document is a press release from Ryvu Therapeutics S.A. announcing the presentation of new clinical trial data (RIVER-81, POTAMI-61, etc.) at the 2025 American Society of Hematology (ASH) Annual Meeting. It provides detailed clinical trial results, including efficacy and safety data, which are typical of corporate announcements regarding research and development progress. Since it does not fit into financial reporting categories like 10-K or IR, and is not a simple notice of a report publication (it contains the actual data highlights), it is best classified as a general regulatory filing/announcement.
2025-12-07 English
Nowe dane kliniczne z badań romacyklibu (RVU120) RIVER-81 i POTAMI-61 prezentowane podczas dorocznej konferencji Amerykańskiego Towarzystwa Hematologicznego (ASH) 2025 / New Clinical Data from RIVE...
Regulatory Filings Classification · 1% confidence The document is a corporate announcement from Ryvu Therapeutics S.A. regarding the presentation of clinical trial data (romaciclib/RVU120 and dapolsertib) at the American Society of Hematology (ASH) 2025 conference. It provides detailed summaries of clinical study results (RIVER-81, POTAMI-61, REMARK, JASPIS-01) and directs readers to posters and webinars. While it contains technical data, it is an announcement of research findings and upcoming presentations rather than a formal financial report, audit, or regulatory filing. It fits best under 'Regulatory Filings' (RNS) as a general corporate announcement of material information regarding clinical progress.
2025-12-07 Polish
Terminy przekazywania raportów okresowych w 2026 roku / Publication dates for periodic reports in 2026 - Content (EN)
Report Publication Announcement Classification · 1% confidence The document is a short announcement (1223 characters) from Ryvu Therapeutics S.A. that lists the scheduled publication dates for its periodic financial reports (annual, quarterly, and semi-annual) for the year 2026. It does not contain the actual financial reports themselves, but rather serves as a notification of when those reports will be released. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-11-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.